Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BMS-663068 with High-fat Meal and Increased Gastric pH
NCT02666053Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jan 2016
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fostemsavir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by ViiV Healthcare. Primary endpoints: Maximum observed plasma concentration and Area under the plasma concentration-time curve from time zero extrapolated to infinity. Started Jan 2016; status: completed.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02666053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02666053.